Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Senhwa Biosciences stock

6492.TWO
TW0006492002

Price

42.70 TWD
Today +/-
+0 TWD
Today %
+0 %

Senhwa Biosciences stock price

TWD
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Senhwa Biosciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Senhwa Biosciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Senhwa Biosciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Senhwa Biosciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Senhwa Biosciences Stock Price History

DateSenhwa Biosciences Price
1/21/202542.70 TWD
1/20/202541.65 TWD

Senhwa Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Senhwa Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Senhwa Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Senhwa Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Senhwa Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Senhwa Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Senhwa Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Senhwa Biosciences’s growth potential.

Senhwa Biosciences Revenue, EBIT and net profit per share

DateSenhwa Biosciences RevenueSenhwa Biosciences EBITSenhwa Biosciences Net Income
20231 M TWD-311.11 M TWD-296.31 M TWD
20221 M TWD-356.12 M TWD-349.63 M TWD
2021550,000 TWD-346.32 M TWD-329.26 M TWD
2020617,000 TWD-359.26 M TWD-354.88 M TWD
2019300,000 TWD-393.8 M TWD-391.43 M TWD
2018733,000 TWD-387.47 M TWD-375.85 M TWD
20170 TWD-375.39 M TWD-371.9 M TWD
2016128,000 TWD-258.02 M TWD-255.02 M TWD
20150 TWD-201.02 M TWD-194 M TWD
201423.63 M TWD-163.18 M TWD-155.63 M TWD
201326.26 M TWD-116.28 M TWD-113.18 M TWD
20120 TWD-903,000 TWD-669,000 TWD

Senhwa Biosciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M TWD)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M TWD)NET INCOME (M TWD)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201220132014201520162017201820192020202120222023
02623000000011
---11.54---------
--7.69-8.70--------200.00-200.00
0-20000000000
0-113-155-194-255-371-375-391-354-329-349-296
--37.1725.1631.4445.491.084.27-9.46-7.066.08-15.19
34.945.1365.1267.2467.2673.6976.476.4678.9989.6489.1989.19
------------
Details

Keystats

ⓘ

Revenue and Growth

The Senhwa Biosciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Senhwa Biosciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B TWD)RECEIVABLES (k TWD)OTHER REC. (k TWD)INVENTORIES (M TWD)OTHER CURRENT LIAB. (M TWD)CURRENT ASSETS (B TWD)TANGIBLE ASSETS (M TWD)LONG-T. INVEST. (k TWD)LONG-T. REC. (M TWD)INTANGIBLE ASSETS (k TWD)GOODWILL (M TWD)OTHER NON-CURRENT ASSETS (M TWD)NON-CURRENT ASSETS (M TWD)TOTAL ASSETS (B TWD)LIABILITIESCOMMON STOCK (M TWD)ADDITIONAL PAID-IN CAPITAL (B TWD)RETAINED EARNINGS (M TWD)OTHER EQUITY (M TWD)UNREAL. GAINS/LOSSES (M TWD)EQUITY (B TWD)LIABILITIES (M TWD)PROVISIONS (M TWD)OTHER SHORT-TERM LIAB. (M TWD)SHORT-TERM DEBTS (M TWD)LONG-TERM DEBT PORTION (M TWD)SHORT-TERM REC. (M TWD)LONG-T. LIAB. (M TWD)DEFERRED TAXES (M TWD)OTHER LIAB. (M TWD)LONG-T. LIABILITIES (M TWD)DEBT (M TWD)TOTAL CAPITAL (B TWD)
201220132014201520162017201820192020202120222023
                       
0.330.750.840.730.511.61.230.842.372.031.621.32
00000013333018900
0000009304913342675690
000000000000
0.020.852.383.3610.3614.639.511.5114.3511.717.7617.17
0.330.760.840.740.521.621.240.852.382.041.641.34
001.941.461.945.793.678.49.915.4215.7514.37
0000128128130130130130130130
000000000000
00732456736409118140650231
000000000000
69.6169.6170.644.563.982.51.911.91.881.321.542.02
69.6169.6173.316.486.798.835.8310.4411.916.9317.4216.76
0.40.820.910.740.531.621.250.862.42.061.651.35
                       
339.99622.33654.93654.93657.86743.93744.76744.99896.58897.44897.44897.44
0.060.30.40.250.111.380.840.481.791.441.120.77
-0.67-113.18-155.63-185.26-265.16-558.88-375.85-391.78-354.88-329.26-349.63-296.31
00.494.196.755.360.652.30.25-3.39-5.241.351.49
000000000000
0.40.810.90.730.511.571.210.832.332.011.671.37
000000000000
00011.818.9655.1432.8421.4447.5975.6322.0432.37
0.3914.5213.583.781.852.73.712.162.31.432.734.2
000000000000
00000005.7311.385.178.186.31
0.3914.5213.5815.5820.8257.8336.5529.3261.2782.2332.9542.89
00000001.817.7310.217.983.29
000000000000
000000000000
00000001.817.7310.217.983.29
0.3914.5213.5815.5820.8257.8336.5531.1368.9992.4440.9346.18
0.40.830.920.750.531.631.250.862.42.11.711.41
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Senhwa Biosciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Senhwa Biosciences's financial health and stability.

Assets

Senhwa Biosciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Senhwa Biosciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Senhwa Biosciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Senhwa Biosciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M TWD)DEPRECIATION (M TWD)DEFERRED TAXES (M TWD)CHANGES IN WORKING CAPITAL (M TWD)NON-CASH ITEM (M TWD)PAID INTEREST (M TWD)PAID TAXES (M TWD)NET CASH FLOW FROM OPERATING ACTIVITIES (M TWD)CAPITAL EXPENDITURES (M TWD)CASH FLOW FROM INVESTING ACTIVITIES (M TWD)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M TWD)INTEREST INCOME AND EXPENSES (M TWD)NET DEBT CHANGE (M TWD)NET CHANGE IN EQUITY (B TWD)CASH FLOW FROM FINANCING ACTIVITIES (B TWD)CASH FLOW FROM OTHER FINANCING ACTIVITIES (TWD)TOTAL DIVIDENDS PAID (M TWD)NET CHANGE IN CASH FLOW (B TWD)FREE CASH FLOW (M TWD)SHARE-BASED COMPENSATION (M TWD)
20122013201420152016201720182019202020212022
0-113-155-191-254-371-378-389-354-328-348
00001228767
00000000000
01435339-4-92632-53
0211102935647-10-5
00000000000
000060-300-11
0-96-140-174-220-326-374-384-272-300-399
00-20-1-500000
00-366-1-400000
00-1660100000
00000000000
0000000-54-4-6
0.40.520.23001.42001.8-0.03-0.01
0.40.520.23001.420-0.011.81-0.03-0.02
-----------
00000000000
0.40.420.08-0.11-0.221.09-0.37-0.391.53-0.34-0.41
-0.43-96.2-143.73-174.03-222.53-331.97-374.75-384.5-273.07-300.45-400.34
00000000000

Senhwa Biosciences stock margins

The Senhwa Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Senhwa Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Senhwa Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Senhwa Biosciences's sales revenue. A higher gross margin percentage indicates that the Senhwa Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Senhwa Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Senhwa Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Senhwa Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Senhwa Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Senhwa Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Senhwa Biosciences Margin History

Senhwa Biosciences Gross marginSenhwa Biosciences Profit marginSenhwa Biosciences EBIT marginSenhwa Biosciences Profit margin
202355.2 %-31,111.1 %-29,630.6 %
202250.5 %-35,611.5 %-34,963.2 %
202158.73 %-62,966.55 %-59,864.91 %
202056.89 %-58,226.75 %-57,516.69 %
201912.67 %-131,266.66 %-130,475.33 %
201810.23 %-52,860.57 %-51,275.58 %
201755.2 %0 %0 %
2016100 %-201,574.22 %-199,230.46 %
201555.2 %0 %0 %
20140.72 %-690.71 %-658.74 %
2013-9.65 %-442.77 %-430.96 %
201255.2 %0 %0 %

Senhwa Biosciences Stock Sales Revenue, EBIT, Earnings per Share

The Senhwa Biosciences earnings per share therefore indicates how much revenue Senhwa Biosciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Senhwa Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Senhwa Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Senhwa Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Senhwa Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Senhwa Biosciences Revenue, EBIT and net profit per share

DateSenhwa Biosciences Sales per ShareSenhwa Biosciences EBIT per shareSenhwa Biosciences Earnings per Share
20230.01 TWD-3.49 TWD-3.32 TWD
20220.01 TWD-3.99 TWD-3.92 TWD
20210.01 TWD-3.86 TWD-3.67 TWD
20200.01 TWD-4.55 TWD-4.49 TWD
20190 TWD-5.15 TWD-5.12 TWD
20180.01 TWD-5.07 TWD-4.92 TWD
20170 TWD-5.09 TWD-5.05 TWD
20160 TWD-3.84 TWD-3.79 TWD
20150 TWD-2.99 TWD-2.89 TWD
20140.36 TWD-2.51 TWD-2.39 TWD
20130.58 TWD-2.58 TWD-2.51 TWD
20120 TWD-0.03 TWD-0.02 TWD

Senhwa Biosciences business model

Senhwa Biosciences is one of the most popular companies on Eulerpool.com.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Senhwa Biosciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Senhwa Biosciences historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Senhwa Biosciences shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Senhwa Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Senhwa Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Senhwa Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Senhwa Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Senhwa Biosciences.

Senhwa Biosciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2021-1.01 TWD-0.92 TWD (8.95 %)2021 Q4
9/30/2021-1.24 TWD-0.97 TWD (21.55 %)2021 Q3
6/30/2021-0.89 TWD-0.76 TWD (14.5 %)2021 Q2
1

Senhwa Biosciences shareholders

%
Name
Stocks
Change
Date
4.88745 % Ding Li Development Company Ltd.4,386,00006/30/2024
4.73368 % Panlabs Biologics Inc.4,248,00006/30/2024
3.63717 % Hu Pi Hua Investment Ltd.3,264,00006/30/2024
2.06040 % Pointer Ventures Inc.1,849,00006/30/2024
2.03031 % Hu (Benny)1,822,00006/30/2024
1.52106 % Yunde Co., Ltd.1,365,00006/30/2024
1.52106 % Changhe Co., Ltd.1,365,00006/30/2024
1.51103 % Yuan Qing Investment Corporation Ltd.1,356,00006/30/2024
1.38511 % Chuanpu Investment Holdings Co., Ltd.1,243,00006/30/2024
1.28928 % Wu (Thomas)1,157,00006/30/2024
1
2

Senhwa Biosciences Executives and Management Board

Ms. Yeu-Chuyr Chang

Senhwa Biosciences Independent Director
Compensation 600,000 TWD

Mr. Tong-Young Lee

Senhwa Biosciences Independent Director
Compensation 600,000 TWD

Mr. Yung-Lin Ma

Senhwa Biosciences Independent Director
Compensation 600,000 TWD

Mr. Benny Hu

(73)
Senhwa Biosciences Chairman of the Board (since 2012)

Ms. Sarah Chang

Senhwa Biosciences Chief Financial Officer, Deputy General Manager, Head of Finance & Administration, Corporate Governance Officer
1
2

Most common questions regarding Senhwa Biosciences

What is the P/E ratio of Senhwa Biosciences 2025?

The P/E ratio cannot be calculated for Senhwa Biosciences at the moment.

What is the P/S ratio of Senhwa Biosciences 2025?

The P/S cannot be calculated for Senhwa Biosciences currently.

What is the Quality Investing of Senhwa Biosciences?

The Quality Investing for Senhwa Biosciences is 3/10.

What is the revenue of Senhwa Biosciences 2025?

The revenue cannot currently be calculated for Senhwa Biosciences.

How high is the profit of Senhwa Biosciences 2025?

The profit cannot currently be calculated for Senhwa Biosciences.

What is the business model of Senhwa Biosciences

No history available for Senhwa Biosciences.

What is the Senhwa Biosciences dividend?

Senhwa Biosciences pays a dividend of 0 TWD distributed over payouts per year.

How often does Senhwa Biosciences pay dividends?

The dividend cannot currently be calculated for Senhwa Biosciences or the company does not pay out a dividend.

What is the Senhwa Biosciences ISIN?

The ISIN of Senhwa Biosciences is TW0006492002.

What is the Senhwa Biosciences ticker?

The ticker of Senhwa Biosciences is 6492.TWO.

How much dividend does Senhwa Biosciences pay?

Over the past 12 months, Senhwa Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Senhwa Biosciences is expected to pay a dividend of 0 TWD.

What is the dividend yield of Senhwa Biosciences?

The current dividend yield of Senhwa Biosciences is .

When does Senhwa Biosciences pay dividends?

Senhwa Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Senhwa Biosciences?

Senhwa Biosciences paid dividends every year for the past 0 years.

What is the dividend of Senhwa Biosciences?

For the upcoming 12 months, dividends amounting to 0 TWD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Senhwa Biosciences located?

Senhwa Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Senhwa Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Senhwa Biosciences from 3/4/2025 amounting to 0 TWD, you needed to have the stock in your portfolio before the ex-date on 3/4/2025.

When did Senhwa Biosciences pay the last dividend?

The last dividend was paid out on 3/4/2025.

What was the dividend of Senhwa Biosciences in the year 2024?

In the year 2024, Senhwa Biosciences distributed 0 TWD as dividends.

In which currency does Senhwa Biosciences pay out the dividend?

The dividends of Senhwa Biosciences are distributed in TWD.

All fundamentals about Senhwa Biosciences

Our stock analysis for Senhwa Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Senhwa Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.